BRPI0611717A2 - composto, composiÇço farmacÊutica e uso do composto - Google Patents

composto, composiÇço farmacÊutica e uso do composto

Info

Publication number
BRPI0611717A2
BRPI0611717A2 BRPI0611717-1A BRPI0611717A BRPI0611717A2 BR PI0611717 A2 BRPI0611717 A2 BR PI0611717A2 BR PI0611717 A BRPI0611717 A BR PI0611717A BR PI0611717 A2 BRPI0611717 A2 BR PI0611717A2
Authority
BR
Brazil
Prior art keywords
compound
compounds
pharmaceutical composition
akt
inhibit
Prior art date
Application number
BRPI0611717-1A
Other languages
English (en)
Inventor
Donna J Armstrong
Essa H Hu
Michael J Kelly
Mark E Layton
Yiwei Li
Jun Liang
Kevin J Rodzinak
Michael A Rossi
Philip E Sanderson
Jiabing Wang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0611717A2 publication Critical patent/BRPI0611717A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSTO, COMPOSIÇçO FARMACÊUTICA E USO DO COMPOSTO. A presente invenção provê compostos nafliridina substituidos que inibem a atividade de Akt. Em particular, os compostos descritos seletivamente inibem uma ou duas das isoformas de Akt. A invenção também provê composições compreendendo estes compostos inibidores e métodos de inibir a atividade de Akt por administração dos compostos a um paciente em necessidade de tratamento de câncer.
BRPI0611717-1A 2005-06-10 2006-06-07 composto, composiÇço farmacÊutica e uso do composto BRPI0611717A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68972605P 2005-06-10 2005-06-10
US73418805P 2005-11-07 2005-11-07
PCT/US2006/022079 WO2006135627A2 (en) 2005-06-10 2006-06-07 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
BRPI0611717A2 true BRPI0611717A2 (pt) 2009-01-13

Family

ID=37532789

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0611717-1A BRPI0611717A2 (pt) 2005-06-10 2006-06-07 composto, composiÇço farmacÊutica e uso do composto

Country Status (22)

Country Link
US (1) US8008317B2 (pt)
EP (1) EP1898903B8 (pt)
JP (1) JP5055494B2 (pt)
KR (1) KR100959771B1 (pt)
AU (1) AU2006258124B8 (pt)
BR (1) BRPI0611717A2 (pt)
CA (1) CA2610888C (pt)
CR (1) CR9580A (pt)
DK (1) DK1898903T3 (pt)
EC (1) ECSP077980A (pt)
ES (1) ES2409168T3 (pt)
HR (1) HRP20130429T1 (pt)
IL (1) IL187690A (pt)
MX (1) MX2007015578A (pt)
NI (1) NI200700320A (pt)
NO (1) NO20080150L (pt)
NZ (1) NZ563423A (pt)
PL (1) PL1898903T3 (pt)
PT (1) PT1898903E (pt)
RU (1) RU2421454C2 (pt)
TW (1) TW200800166A (pt)
WO (1) WO2006135627A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1784175A4 (en) 2004-08-23 2009-07-22 Merck & Co Inc INHIBITORS OF ACT ACTIVITY
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
DK1898903T3 (da) 2005-06-10 2013-07-01 Merck Sharp & Dohme Inhibitorer af Akt-aktivitet
TW200806670A (en) * 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
AU2007327992A1 (en) * 2006-12-06 2008-06-12 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AR067413A1 (es) 2007-07-05 2009-10-07 Genentech Inc Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
CL2008002398A1 (es) 2007-08-14 2009-07-31 Bayer Ip Gmbh Compuestos derivados de 6-(fenil piperidina) pirimidinas fusionadas con imidazol, triazol o pirozol, inhibidores de la via pi3k/akt; composicion farmaceutica; combinacion farmaceutica; y uso de los compuestos para el tratamiento de la neoplasia benigna y/o maligna y para el cancer.
JP2011522047A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
CA2726317A1 (en) * 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2586311B1 (de) 2008-07-17 2016-12-14 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
WO2010088177A1 (en) * 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
AU2010213192A1 (en) 2009-02-13 2011-08-04 Bayer Intellectual Property Gmbh Fused pyrimidines
JP5667085B2 (ja) 2009-02-13 2015-02-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔインヒビターとしての融合されたピリミジン
US8481503B2 (en) * 2009-03-06 2013-07-09 Merck Sharp & Dohme Corp. Combination cancer therapy with an AKT inhibitor and other anticancer agents
US8614221B2 (en) * 2009-03-11 2013-12-24 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8168652B2 (en) 2009-03-12 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2266985A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
EP2473495A1 (en) 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
WO2011075383A1 (en) * 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Inhibitors of akt activity
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
US8975265B2 (en) * 2010-07-12 2015-03-10 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrimidines and —pyridines
ES2603032T3 (es) * 2010-07-15 2017-02-23 Bayer Intellectual Property Gmbh Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas
DK2694510T3 (en) 2011-04-07 2016-01-18 Bayer Ip Gmbh IMIDAZOPYRIDAZINER AS AKT kinase inhibitors
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
MX354373B (es) * 2012-05-17 2018-02-28 Genentech Inc Proceso para hacer compuestos de ciclopentapirimidina hidroxilada y sus sales.
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
MA38287B1 (fr) 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3091016A1 (en) 2015-05-05 2016-11-09 Technische Universität Dortmund Kinase inhibitors and their use in cancer therapy
AU2016368257C1 (en) * 2015-12-07 2019-12-05 Suzhou Sinovent Pharmaceuticals Co., Ltd. Five-membered heterocyclic amides wnt pathway inhibitor
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
EP4653429A1 (en) 2017-09-07 2025-11-26 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
JP7769388B2 (ja) 2019-12-12 2025-11-13 ティン セラピューティクス，インコーポレイテッド 聴覚損失の予防及び治療のための組成物及び方法
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
CA3236906A1 (en) * 2021-11-05 2023-05-11 Georgiamune Inc. Akt3 modulators
WO2025196160A1 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions
WO2025196161A2 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
DE69525978T2 (de) * 1995-06-06 2002-12-19 Pfizer Trizyclische 5,6-dihydro-9h-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-alpha)pyridine
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
EP1379251B1 (en) 2001-04-10 2008-07-09 Merck & Co., Inc. Inhibitors of akt activity
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1494676B1 (en) 2002-04-08 2013-05-08 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of akt activity
CA2480800C (en) * 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
AU2003226250B2 (en) 2002-04-08 2007-08-16 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1496906A4 (en) 2002-04-08 2006-05-03 Merck & Co Inc HEMMER OF ACT ACTIVITY
BR0313743A (pt) * 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
CA2501365C (en) 2002-10-30 2011-05-31 Merck & Co., Inc. Inhibitors of akt activity
ATE446752T1 (de) 2003-04-24 2009-11-15 Merck & Co Inc Hemmer der akt aktivität
CN1809351A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
AU2004233828B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP4673300B2 (ja) 2003-04-24 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
US7563906B2 (en) 2003-10-15 2009-07-21 Ube Industries, Ltd. Indazole derivatives
WO2005100356A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
EP1784175A4 (en) * 2004-08-23 2009-07-22 Merck & Co Inc INHIBITORS OF ACT ACTIVITY
CA2588474A1 (en) 2004-12-02 2006-06-29 Merck & Co., Inc. Inhibitors of akt activity
AU2005316826A1 (en) 2004-12-15 2006-06-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1850843A4 (en) * 2005-02-14 2012-02-15 Merck Sharp & Dohme INHIBITORS OF ACT ACTIVITY
AU2006235314B2 (en) 2005-04-12 2011-01-20 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
DK1898903T3 (da) 2005-06-10 2013-07-01 Merck Sharp & Dohme Inhibitorer af Akt-aktivitet
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Also Published As

Publication number Publication date
US20100222321A1 (en) 2010-09-02
IL187690A0 (en) 2008-11-03
HRP20130429T1 (en) 2013-06-30
MX2007015578A (es) 2008-03-06
WO2006135627A3 (en) 2008-07-31
TW200800166A (en) 2008-01-01
KR20080016627A (ko) 2008-02-21
AU2006258124B2 (en) 2009-09-03
EP1898903A4 (en) 2010-07-21
IL187690A (en) 2012-06-28
NZ563423A (en) 2010-05-28
WO2006135627A2 (en) 2006-12-21
EP1898903B8 (en) 2013-05-15
KR100959771B1 (ko) 2010-05-28
CR9580A (es) 2008-09-23
ECSP077980A (es) 2008-01-23
JP2009501698A (ja) 2009-01-22
EP1898903A2 (en) 2008-03-19
CA2610888A1 (en) 2006-12-21
RU2421454C2 (ru) 2011-06-20
EP1898903B1 (en) 2013-03-27
PL1898903T3 (pl) 2013-08-30
NO20080150L (no) 2008-03-10
NI200700320A (es) 2008-06-17
DK1898903T3 (da) 2013-07-01
JP5055494B2 (ja) 2012-10-24
RU2008100045A (ru) 2009-07-20
US8008317B2 (en) 2011-08-30
AU2006258124A1 (en) 2006-12-21
ES2409168T3 (es) 2013-06-25
PT1898903E (pt) 2013-06-28
AU2006258124B8 (en) 2010-01-07
CA2610888C (en) 2011-02-08

Similar Documents

Publication Publication Date Title
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
BRPI0815708B8 (pt) composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
SV2011003786A (es) Compuestos quimicos 251
WO2006091395A3 (en) Inhibitors of akt activity
BRPI0511139B8 (pt) compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
BRPI0519424B8 (pt) compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0622054B8 (pt) composto e composição farmacêutica
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112012006010A2 (pt) composto de glicina
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
WO2006110638A3 (en) Inhibitors of akt activity
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
WO2006068796A3 (en) Inhibitors of akt activity
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: ALTERADO DE: MERCK AND CO., INC.

B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION, (US)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]